论文部分内容阅读
目的观察奥沙利铂联合替吉奥方案与FOLFOX4方案治疗晚期直肠癌的近期疗效和不良反应。方法将36例晚期直肠癌患者随机分为观察组和对照组,均化疗至少2个周期,比较近期疗效及不良反应。结果两组有效率比较差异无统计学意义(P>0.05)。不良反应中对照组静脉炎发生率显著高于观察组,且差异有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥方案与FOLFOX4方案治疗晚期直肠癌的疗效相近,但前者具有用药更为方便,耐受性稍好,安全性更好等优点,值得临床一线使用。
Objective To observe the short-term effects and side effects of oxaliplatin combined with tiagrogol and FOLFOX4 regimen in the treatment of advanced rectal cancer. Methods Thirty-six patients with advanced colorectal cancer were randomly divided into observation group and control group, all with at least 2 cycles of chemotherapy, and the short-term efficacy and adverse reactions were compared. Results There was no significant difference in the effective rate between the two groups (P> 0.05). Adverse reactions phlebitis in the control group was significantly higher than the observation group, and the difference was statistically significant (P <0.05). Conclusion The combination of oxaliplatin and tioguanide is similar to FOLFOX4 in the treatment of advanced rectal cancer. However, the former has the advantages of more convenient medication, better tolerability and better safety, which is worthy of clinical use.